Cargando…

Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR

BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Restelli, Umberto, García-Goñi, Manuel, Lew-Starowicz, Michal, Mierzejewski, Pawel, Silvola, Sofia, Mayoral-van Son, Jacqueline, Croce, Davide, Rocca, Paola, Crespo-Facorro, Benedicto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/
https://www.ncbi.nlm.nih.gov/pubmed/32648201
http://dx.doi.org/10.1007/s40261-020-00944-0
_version_ 1783575257531023360
author Restelli, Umberto
García-Goñi, Manuel
Lew-Starowicz, Michal
Mierzejewski, Pawel
Silvola, Sofia
Mayoral-van Son, Jacqueline
Croce, Davide
Rocca, Paola
Crespo-Facorro, Benedicto
author_facet Restelli, Umberto
García-Goñi, Manuel
Lew-Starowicz, Michal
Mierzejewski, Pawel
Silvola, Sofia
Mayoral-van Son, Jacqueline
Croce, Davide
Rocca, Paola
Crespo-Facorro, Benedicto
author_sort Restelli, Umberto
collection PubMed
description BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medical costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) assuming the Italian and Spanish National Health Service perspective. METHODS: A health economic model was developed based on a previously published model. The analysis considered direct medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A deterministic sensitivity analysis was implemented to test the robustness of the results. RESULTS: The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization of + 24.5%. CONCLUSIONS: The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40261-020-00944-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7452921
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74529212020-09-02 Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR Restelli, Umberto García-Goñi, Manuel Lew-Starowicz, Michal Mierzejewski, Pawel Silvola, Sofia Mayoral-van Son, Jacqueline Croce, Davide Rocca, Paola Crespo-Facorro, Benedicto Clin Drug Investig Original Research Article BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medical costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) assuming the Italian and Spanish National Health Service perspective. METHODS: A health economic model was developed based on a previously published model. The analysis considered direct medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A deterministic sensitivity analysis was implemented to test the robustness of the results. RESULTS: The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization of + 24.5%. CONCLUSIONS: The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40261-020-00944-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-07-09 2020 /pmc/articles/PMC7452921/ /pubmed/32648201 http://dx.doi.org/10.1007/s40261-020-00944-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research Article
Restelli, Umberto
García-Goñi, Manuel
Lew-Starowicz, Michal
Mierzejewski, Pawel
Silvola, Sofia
Mayoral-van Son, Jacqueline
Croce, Davide
Rocca, Paola
Crespo-Facorro, Benedicto
Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title_full Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title_fullStr Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title_full_unstemmed Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title_short Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
title_sort cost of relapse management in patients with schizophrenia in italy and spain: comparison between lurasidone and quetiapine xr
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/
https://www.ncbi.nlm.nih.gov/pubmed/32648201
http://dx.doi.org/10.1007/s40261-020-00944-0
work_keys_str_mv AT restelliumberto costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT garciagonimanuel costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT lewstarowiczmichal costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT mierzejewskipawel costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT silvolasofia costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT mayoralvansonjacqueline costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT crocedavide costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT roccapaola costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr
AT crespofacorrobenedicto costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr